Zevra Therapeutics Reports Preliminary Q2 2024 Revenue of $4.2-$4.6 Million, Net Loss Widens to $18.9-$19.8 Million

ZEVRA THERAPEUTICS, INC.

2025-Q2 EPS reported -$0.87 vs consensus $1.53 ▼ miss (-156.9%)

Revenue for Q2 2024 expected between $4.2M and $4.6M, down from $8.47M in Q2 2023 which included a $5.0M milestone payment from AZSTARYS license.
Net loss for Q2 2024 estimated at $18.9M to $19.8M, compared to a $2.6M net loss in the prior-year quarter.
Preliminary diluted net loss per share ranges from ($0.47) to ($0.45), versus ($0.08) in Q2 2023.
Cash and cash equivalents as of June 30, 2024 were approximately $49.3 million.
The decrease in revenue is partially offset by reimbursements under AZSTARYS License Agreement and increased French expanded access program reimbursements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.